| Cash flow (USD) | Q2 2026 ended Jun 27, 2026 | Q1 2026 ended Mar 28, 2026 | Q4 2025 ended Dec 31, 2025 | Q3 2025 ended Sep 27, 2025 | Q2 2025 ended Jun 28, 2025 | Q1 2026 ended Mar 29, 2025 | Q4 2025 ended Dec 31, 2024 | Q3 2025 ended Sep 28, 2024 |
|---|---|---|---|---|---|---|---|---|
| Net income | 1.74B | 1.65B | 1.98B | 1.62B | 1.62B | 1.51B | 1.83B | 1.63B |
| Depreciation and amortization | 331.00M | 306.00M | 292.00M | 227.00M | 256.00M | 276.00M | 304.00M | 291.00M |
| Stock-based compensation | 82.00M | 83.00M | 84.00M | 70.00M | 81.00M | 75.00M | 79.00M | 68.00M |
| Cash from operations | 2.13B | 1.19B | 3.46B | 2.24B | 1.40B | 723.00M | 3.29B | 2.17B |
| Capital expenditure | -450.00M | -376.00M | -465.00M | -404.00M | -294.00M | -362.00M | -480.00M | -272.00M |
| Free cash flow | 1.68B | 816.00M | 2.99B | 1.83B | 1.10B | 361.00M | 2.81B | 1.89B |
| Acquisitions | 0 | -8.87B | 0 | -4.04B | 0 | 0 | 0 | -3.13B |
| Cash from investing | 164.00M | -8.96B | 891.00M | -4.12B | -288.00M | -527.00M | 20.00M | -3.58B |
| Dividends paid | -175.00M | -162.00M | -162.00M | -163.00M | -162.00M | -149.00M | -149.00M | -150.00M |
| Share buybacks | -1.00B | -3.00B | -37.00M | -963.00M | 0 | -2.00B | -1.00B | 0 |
| Net debt issued | 0 | 3.83B | 4.13B | 0 | -787.00M | 2.00B | -2.50B | -1.11B |
| Cash from financing | -1.57B | 1.09B | 3.53B | -632.00M | -991.00M | -102.00M | -3.67B | -1.19B |
| Net change in cash | 817.00M | -6.60B | 7.87B | -2.59B | 431.00M | 132.00M | -630.00M | -2.43B |
From Thermo Fisher Scientific's 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.